An Observational Study Program to Investigate the Effectiveness of Aflibercept 8 mg Used in DME and nAMD in a Real-world Setting
Latest Information Update: 27 Apr 2025
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms SPECTRUM
- Sponsors Bayer
Most Recent Events
- 20 Nov 2024 Planned primary completion date changed from 31 Oct 2027 to 30 Oct 2027.
- 22 Feb 2024 Status changed from not yet recruiting to recruiting.
- 30 Jan 2024 Planned End Date changed from 30 Jun 2028 to 31 Jan 2028.